Robust Trading Volumes and Value Turnover
On 6 August 2026, Morepen Laboratories Ltd (symbol: MOREPENLAB) emerged as one of the most actively traded equities by value on the Indian stock exchanges. The company recorded a staggering total traded volume of 6.88 crore shares, translating into a total traded value of ₹552.36 crores. This level of liquidity is notable for a small-cap stock with a market capitalisation of approximately ₹4,268 crores.
The stock opened at ₹76.39, slightly below the previous close of ₹76.95, but quickly gained momentum to touch an intraday high of ₹83.50, representing a 5.59% rise from the previous close. The last traded price (LTP) stood at ₹81.15 as of 11:34 AM, reflecting a strong upward trajectory within a relatively narrow trading range of ₹0.15 near the day’s low.
Price Momentum and Technical Strength
Morepen Laboratories has been on a consistent upward trend, gaining for five consecutive trading sessions and delivering an impressive 43.97% return over this period. The stock’s performance today outpaced its sector by 5.07% and the broader Sensex by 5.18%, signalling strong relative strength within the Pharmaceuticals & Biotechnology space.
Technically, the stock is trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — indicating sustained bullish momentum. The weighted average price suggests that a significant volume of shares exchanged hands close to the day’s low, hinting at strong buying interest at lower price levels and a potential base for further gains.
Institutional Participation and Delivery Volumes
Investor participation has surged notably, with delivery volumes on 5 August reaching 2.57 crore shares, a remarkable 331.09% increase compared to the five-day average delivery volume. This spike in delivery volumes is a key indicator of genuine buying interest rather than speculative intraday trading, often favoured by institutional investors and long-term market participants.
Liquidity metrics further reinforce the stock’s tradability, with the current trading value supporting a trade size of nearly ₹5.96 crores based on 2% of the five-day average traded value. Such liquidity levels are conducive for institutional investors seeking sizeable positions without significant market impact.
Momentum building strong! This Mid Cap from NBFC is on our MomentumNow radar. Other investors are catching on – will you join?
- - Building momentum strength
- - Investor interest growing
- - Limited time advantage
Mojo Score Upgrade Reflects Improving Fundamentals
MarketsMOJO’s proprietary Mojo Score for Morepen Laboratories currently stands at 64.0, categorised as a ‘Hold’ rating. This marks a positive revision from the previous ‘Sell’ grade, which was updated on 3 August 2026. The upgrade reflects improving financial metrics and market sentiment, signalling a stabilisation in the company’s fundamentals and outlook.
Despite being a small-cap stock, Morepen Laboratories has demonstrated resilience and growth potential within the Pharmaceuticals & Biotechnology sector, which continues to attract investor interest due to its defensive characteristics and innovation-driven growth prospects.
Sector and Market Context
The Pharmaceuticals & Biotechnology sector has shown modest gains, with a sector return of 0.44% on the day, while the Sensex posted a marginal 0.08% increase. Morepen Laboratories’ outperformance relative to both benchmarks highlights its emerging leadership among peers and its ability to capitalise on sector tailwinds.
Investors should note that the stock’s recent rally has been supported by a combination of strong volume, institutional buying, and technical strength, factors that often precede sustained price appreciation in mid and small-cap stocks.
Holding Morepen Laboratories Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Investor Takeaway and Outlook
Morepen Laboratories Ltd’s recent price action and trading activity suggest a growing institutional conviction in the stock’s medium-term prospects. The combination of a strong volume surge, rising delivery volumes, and a positive Mojo Score upgrade indicates that the stock is transitioning from a previously weak phase into a more stable and potentially rewarding investment opportunity.
However, investors should remain mindful of the inherent volatility associated with small-cap stocks and the broader sector dynamics. While the Pharmaceuticals & Biotechnology sector offers defensive qualities, regulatory developments and competitive pressures can influence stock performance.
Given the current momentum and technical indicators, Morepen Laboratories appears well-positioned to sustain its upward trajectory, provided it continues to deliver on operational and financial fronts. Monitoring institutional activity and volume patterns will be crucial for investors seeking to capitalise on this trend.
Summary of Key Metrics:
- Market Capitalisation: ₹4,268 crores (Small Cap)
- Mojo Score: 64.0 (Hold, upgraded from Sell on 3 Aug 2026)
- Trading Volume (6 Aug 2026): 6.88 crore shares
- Trading Value (6 Aug 2026): ₹552.36 crores
- Price Range (6 Aug 2026): ₹75.11 - ₹83.50
- Last Traded Price (LTP): ₹81.15
- 5-Day Consecutive Gains: 43.97% return
- Delivery Volume (5 Aug 2026): 2.57 crore shares (up 331.09% vs 5-day avg)
- Sector 1-Day Return: 0.44%
- Sensex 1-Day Return: 0.08%
In conclusion, Morepen Laboratories Ltd’s surge in value turnover and institutional interest marks it as a noteworthy contender within the Pharmaceuticals & Biotechnology sector. Its recent upgrade in Mojo Grade and sustained price momentum provide a compelling case for investors to monitor this stock closely as it navigates the evolving market landscape.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
